NCT01537653View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Healthy
Interventions
DRUG

SAR231893 (REGN668)

Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection

DRUG

placebo

Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection

Trial Locations (1)

171-0014

Investigational Site Number 392001, Toshima-Ku

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY